The WHO has paused the hydroxychloroquine arm of a global trial while it investigates safety concerns highlighted by published studies.
List view / Grid view
World Health Organization (WHO)
Filter the results
Dr Saurabh Kumar Banerjee outlines the impact of COVID-19 on immunisation programmes in India and how organisations can hope to mitigate the consequences of missed vaccine doses.
According to a new agreement between Mylan and Gilead, the former has the rights to manufacture and distribute remdesivir in 127 countries, a drug being tested to combat COVID-19.
NICE in the UK has announced it will partner with international collaborations to share its work on COVID-19 and develop guidelines for healthcare professionals.
In light of the COVID-19 pandemic, WHO has asked the pharmaceutical supply chain to swiftly distribute nets and antimalarial medicines in sub-Saharan Africa.
The UK MHRA granted expedited acceptance for the Phase II trial of MRx-4DP0004, a live biotherapy product and targeted immunomodulatory therapy.
Dr Abhishek Dadhich rounds up how the Indian pharmaceutical market has been impacted by the coronavirus pandemic and the steps the country’s government could take to overcome these setbacks.
Whitty will take a leave of absence, effective today, to co-lead a global effort by the World Health Organization (WHO) to accelerate the development of a COVID-19 vaccine.
An open letter from aid organisations and academics has called on the UK government to stipulate conditions for pharmaceutical companies using public funding for COVID-19 vaccines.
Marie Manley and co-authors from Sidley Austin explain the updates to regulations in the EU and UK in light of the COVID-19 coronavirus pandemic.
A new report has revealed the vaccine R&D efforts of 15 of the leading pharmaceutical companies to combat the COVID-19 coronavirus.
The coalition has been formed to find R&D solutions for low- and middle-income countries to limit the impact of the COVID-19 pandemic in areas with fragile healthcare systems.
European Pharmaceutical Review explores how a surge in the number of warning letters for data integrity failings have prompted regulators to publish new guidelines.
A WHO review has concluded that while innovative therapies have been developed for TB and C. diff, other priority pathogens are likely to develop resistance to future therapies.